MMN clinical trials at UCSF

1 research study open to eligible people

Multifocal motor neuropathy is a disorder that causes muscle weakness due to nerve damage. UCSF is comparing a new drug, empasiprubart, with IVIg in adults with MMN to learn more about their safety and effectiveness. Researchers are focused on understanding how these different treatments work.

Showing trials for

  • Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

    open to eligible people ages 18 years and up

    The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months.

    San Francisco, California and other locations

Last updated: